A Full Face Study to Evaluate the Efficacy of Dermapen 4™ Microneedling Device in Addition with MG-CLR Serum for Acne Treatment Over 12 Weeks.

Launched by EQUIPMED USA LLC · Sep 16, 2024

Keywords

ClinConnect Summary

This clinical trial is testing a new treatment for acne using a device called Dermapen 4™ and a special serum called MG-CLR. The goal is to see how effective this combination is in improving acne over a period of 12 weeks. This study is specifically for women aged 18 to 45 who have certain types of skin and a specific level of acne severity. To participate, women must not have used any acne treatments for a month prior to the trial and should not have any other skin issues that could affect the results.

If you join this study, you will be asked to use only the provided products on your face during the trial. It’s important to note that certain conditions, like active skin infections or bleeding disorders, may disqualify you from participating. The trial is not yet recruiting participants, but it aims to provide valuable information about a potential new acne treatment option.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • 1. Female subjects aged between 18-45 years (both ages inclusive)
• • 2. Fitzpatrick skin phototype I to VI.
• • 3. Subjects having IGA score of 2 and 3.
• • 4. Subjects who have not received any kind of treatment for acne 1 month before the start of the study.
• • 5. Subject free of excessive hair, cuts, abrasions, fissures, wounds, lacerations, or any other skin conditions on the face.
• • 6. Subjects who agree not to use any other product/treatment/home remedy/ except the provided products on their face during the study period
• Exclusion Criteria:
• • 1. Subjects with known skin condition that may impact the assessment.
• • 2. Subjects with active Herpes labialis infection.
• • 3. Subjects known to have bleeding and clotting disorders (self-declared).
• • 4. Subjects known to have connective tissue disorders.
• • 5. Subjects with any other signs of significant local irritation or skin disease.
• • 6. Subjects currently taking any medication, which the investigator believes may influence the interpretation of the data.